Steglatro
Payments companies reported to CMS as associated with Steglatro. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Steglatro, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Steglatro
These are the largest totals companies reported as associated with Steglatro. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Samuel Dagogo-Jack | Memphis, TN | Endocrinology, Diabetes & Metabolism | $13,237.79 |
| Antonio Urbina | New York, NY | Infectious Disease | $10,797.01 |
| Roger Bedimo | Dallas, TX | Infectious Disease | $8,934.44 |
| William Herman | Ann Arbor, MI | Endocrinology, Diabetes & Metabolism | $7,437.50 |
| John Fuqua | Indianapolis, IN | Pediatric Endocrinology | $6,882.00 |
| Henry Rodriguez | Tampa, FL | Pediatric Endocrinology | $5,347.50 |
| Julie Surhigh | Royal Oak, MI | Pediatric Endocrinology | $5,150.00 |
| Ambarish Pandey | Dallas, TX | Cardiovascular Disease | $4,396.66 |
| Chandan Sahay | Hazard, KY | Internal Medicine | $3,285.00 |
| Hector Banchs | Carolina, PR | Clinical Cardiac Electrophysiology | $1,125.00 |
Prescribed Steglatro?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.